Bicycle Therapeutics Plc
(NASDAQ : BCYC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-1.25%194.261.3%$534.90m
GILDGilead Sciences, Inc.
-0.39%65.910.9%$358.61m
ALXNAlexion Pharmaceuticals, Inc.
-4.94%102.502.0%$309.45m
ILMNIllumina, Inc.
1.19%301.813.5%$306.83m
BIIBBiogen Inc.
-1.42%235.311.3%$295.44m
CELGCelgene Corporation
0.11%98.711.3%$288.69m
SRPTSarepta Therapeutics, Inc.
-2.36%82.8814.6%$174.65m
AAgilent Technologies, Inc.
0.58%76.841.6%$174.34m
VRTXVertex Pharmaceuticals Incorporated
-0.85%174.501.9%$173.05m
REGNRegeneron Pharmaceuticals, Inc.
-2.09%282.092.6%$168.99m
EXASExact Sciences Corporation
-1.77%104.9824.1%$132.80m
ACADACADIA Pharmaceuticals Inc.
-3.78%40.9913.9%$110.63m
INCYIncyte Corporation
-1.39%78.002.5%$84.52m
BMRNBioMarin Pharmaceutical Inc.
0.64%75.484.3%$71.69m
ALDRAlder Biopharmaceuticals, Inc.
0.48%18.7910.2%$64.25m

Company Profile

Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.